HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.

Abstract
Accessibility to iron chelators including deferoxamine and deferasirox remains obscured in many developing countries. To provide an alternative, the government pharmaceutical organization of Thailand (GPO) manufactured deferiprone which has similar bioequivalent to the standard product. Seventy-three pediatric patients with severe β thalassemias, age range 3.2-19 years, were recruited to a 1-year multicenter prospective, single arm, open label, dose escalating Phase III study of deferiprone to determine its clinical efficacy and safety. Sixty-four patients (87.6%) completed the study with good compliance (>94%). Average deferiprone dose was 79.1±4.3 mg/kg/day. Overall, mean serum ferritin (SF) levels at 1 year were not significantly changed from baseline. However, 45% of patients (response group) had SF reduced >15% from baseline at 1 year with a median reduction of 1,065 ng ml(-1) . Baseline SF was the major factor that predicts clinical efficacy; patients with baseline SF>3,500 ng ml(-1) had the most significant fall of SF at 1 year. A subgroup analysis by MRI-T2* confirmed that the response group had higher baseline liver iron and deferiprone could significantly reduce liver iron overload and normalize levels of ALT at 1 year. Although, gastrointestinal irritation (20.5%) was the most common drug-related adverse events (AEs) followed by transaminitis (16.4%) and neutropenia (6.8%), all patients were well tolerated. There was no mortality and agranulocytosis found in this trial. Monotherapy of deferiprone with appropriate dose adjustment and monitoring for adverse events appeared to be an effective chelation therapy in some patients with good compliance and acceptable safety profiles.
AuthorsVip Viprakasit, Issarang Nuchprayoon, Ampaiwan Chuansumrit, Kitti Torcharus, Bunchoo Pongtanakul, Jiraporn Laothamatas, Somdet Srichairatanakool, Julaporn Pooliam, Siriwat Supajitkasem, Prapat Suriyaphol, Voravarn S Tanphaichitr, Soodsarkorn Tuchinda
JournalAmerican journal of hematology (Am J Hematol) Vol. 88 Issue 4 Pg. 251-60 (Apr 2013) ISSN: 1096-8652 [Electronic] United States
PMID23460233 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 Wiley Periodicals, Inc.
Chemical References
  • Iron Chelating Agents
  • Pyridones
  • deferiprone
  • Ferritins
  • Iron
Topics
  • Acute Disease
  • Administration, Oral
  • Adolescent
  • Blood Transfusion (adverse effects)
  • Child
  • Child, Preschool
  • Drug Administration Schedule
  • Female
  • Ferritins (blood)
  • Humans
  • Iron (metabolism)
  • Iron Chelating Agents (administration & dosage, adverse effects)
  • Iron Overload (drug therapy, etiology, metabolism)
  • Liver (metabolism)
  • Male
  • Prospective Studies
  • Pyridones (administration & dosage, adverse effects)
  • Thailand
  • Treatment Outcome
  • Young Adult
  • beta-Thalassemia (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: